Prostate cancer

Prediction of biochemical failure after external-beam radiation therapy - Kattan nomogram and endorectal MR imaging estimation of tumor volume

Antonio C. Westphalen, Walter J. Koff, Fergus Coakley, Valdair F. Muglia, John M. Neuhaus, Ralph T. Marcus, John Kurhanewicz, Rebecca Smith-Bindman

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Purpose: To determine whether magnetic resonance (MR) imaging and MR spectroscopic imaging findings can improve predictions made with the Kattan nomogram for radiation therapy. Materials and Methods: The institutional review board approved this retrospective HIPAA-compliant study. Ninety-nine men who underwent endorectal MR and MR spectroscopy before externalbeam radiation therapy for prostate cancer (January 1998 to June 2007) were included. Linear predictors were calculated with input variables from the study sample and the Kattan original coefficients. The linear predictor is a single weighted value that combines information of all predictor variables in a model, where the weight of each value is its association with the outcome. Two radiologists independently reviewed all MR images to determine extent of disease; a third independent reader resolved discrepancies. Biochemical failure was defined as a serum prostate-specific antigen level of 2 ng/mL (2 μg/L) or more above nadir. Cox proportional hazard models were used to determine the probabilities of treatment failure (biochemical failure) in 5 years. One model included only the Kattan nomogram data; the other also incorporated imaging findings. The discrimination performance of all models was determined with receiver operating characteristics (ROC) curve analyses. These analyses were followed by an assessment of net risk reclassification. Results: The areas under the ROC curve for the Kattan nomogram and the model incorporating MR imaging findings were 61.1% (95% confidence interval: 58.1%, 64.0%) and 78.0% (95% confidence interval: 75.7%, 80.4%), respectively. Comparison of performance showed that the model with imaging findings performed significantly better than did the model with clinical variables alone (P

Original languageEnglish (US)
Pages (from-to)477-486
Number of pages10
JournalRadiology
Volume261
Issue number2
DOIs
StatePublished - Nov 2011
Externally publishedYes

Fingerprint

Nomograms
Tumor Burden
Prostatic Neoplasms
Magnetic Resonance Spectroscopy
Radiotherapy
Magnetic Resonance Imaging
ROC Curve
Confidence Intervals
Health Insurance Portability and Accountability Act
Research Ethics Committees
Prostate-Specific Antigen
Treatment Failure
Proportional Hazards Models
Weights and Measures
Serum

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Prostate cancer : Prediction of biochemical failure after external-beam radiation therapy - Kattan nomogram and endorectal MR imaging estimation of tumor volume. / Westphalen, Antonio C.; Koff, Walter J.; Coakley, Fergus; Muglia, Valdair F.; Neuhaus, John M.; Marcus, Ralph T.; Kurhanewicz, John; Smith-Bindman, Rebecca.

In: Radiology, Vol. 261, No. 2, 11.2011, p. 477-486.

Research output: Contribution to journalArticle

Westphalen, Antonio C. ; Koff, Walter J. ; Coakley, Fergus ; Muglia, Valdair F. ; Neuhaus, John M. ; Marcus, Ralph T. ; Kurhanewicz, John ; Smith-Bindman, Rebecca. / Prostate cancer : Prediction of biochemical failure after external-beam radiation therapy - Kattan nomogram and endorectal MR imaging estimation of tumor volume. In: Radiology. 2011 ; Vol. 261, No. 2. pp. 477-486.
@article{65df4e841a864be7951ee46894bf7d00,
title = "Prostate cancer: Prediction of biochemical failure after external-beam radiation therapy - Kattan nomogram and endorectal MR imaging estimation of tumor volume",
abstract = "Purpose: To determine whether magnetic resonance (MR) imaging and MR spectroscopic imaging findings can improve predictions made with the Kattan nomogram for radiation therapy. Materials and Methods: The institutional review board approved this retrospective HIPAA-compliant study. Ninety-nine men who underwent endorectal MR and MR spectroscopy before externalbeam radiation therapy for prostate cancer (January 1998 to June 2007) were included. Linear predictors were calculated with input variables from the study sample and the Kattan original coefficients. The linear predictor is a single weighted value that combines information of all predictor variables in a model, where the weight of each value is its association with the outcome. Two radiologists independently reviewed all MR images to determine extent of disease; a third independent reader resolved discrepancies. Biochemical failure was defined as a serum prostate-specific antigen level of 2 ng/mL (2 μg/L) or more above nadir. Cox proportional hazard models were used to determine the probabilities of treatment failure (biochemical failure) in 5 years. One model included only the Kattan nomogram data; the other also incorporated imaging findings. The discrimination performance of all models was determined with receiver operating characteristics (ROC) curve analyses. These analyses were followed by an assessment of net risk reclassification. Results: The areas under the ROC curve for the Kattan nomogram and the model incorporating MR imaging findings were 61.1{\%} (95{\%} confidence interval: 58.1{\%}, 64.0{\%}) and 78.0{\%} (95{\%} confidence interval: 75.7{\%}, 80.4{\%}), respectively. Comparison of performance showed that the model with imaging findings performed significantly better than did the model with clinical variables alone (P",
author = "Westphalen, {Antonio C.} and Koff, {Walter J.} and Fergus Coakley and Muglia, {Valdair F.} and Neuhaus, {John M.} and Marcus, {Ralph T.} and John Kurhanewicz and Rebecca Smith-Bindman",
year = "2011",
month = "11",
doi = "10.1148/radiol.11110457",
language = "English (US)",
volume = "261",
pages = "477--486",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "2",

}

TY - JOUR

T1 - Prostate cancer

T2 - Prediction of biochemical failure after external-beam radiation therapy - Kattan nomogram and endorectal MR imaging estimation of tumor volume

AU - Westphalen, Antonio C.

AU - Koff, Walter J.

AU - Coakley, Fergus

AU - Muglia, Valdair F.

AU - Neuhaus, John M.

AU - Marcus, Ralph T.

AU - Kurhanewicz, John

AU - Smith-Bindman, Rebecca

PY - 2011/11

Y1 - 2011/11

N2 - Purpose: To determine whether magnetic resonance (MR) imaging and MR spectroscopic imaging findings can improve predictions made with the Kattan nomogram for radiation therapy. Materials and Methods: The institutional review board approved this retrospective HIPAA-compliant study. Ninety-nine men who underwent endorectal MR and MR spectroscopy before externalbeam radiation therapy for prostate cancer (January 1998 to June 2007) were included. Linear predictors were calculated with input variables from the study sample and the Kattan original coefficients. The linear predictor is a single weighted value that combines information of all predictor variables in a model, where the weight of each value is its association with the outcome. Two radiologists independently reviewed all MR images to determine extent of disease; a third independent reader resolved discrepancies. Biochemical failure was defined as a serum prostate-specific antigen level of 2 ng/mL (2 μg/L) or more above nadir. Cox proportional hazard models were used to determine the probabilities of treatment failure (biochemical failure) in 5 years. One model included only the Kattan nomogram data; the other also incorporated imaging findings. The discrimination performance of all models was determined with receiver operating characteristics (ROC) curve analyses. These analyses were followed by an assessment of net risk reclassification. Results: The areas under the ROC curve for the Kattan nomogram and the model incorporating MR imaging findings were 61.1% (95% confidence interval: 58.1%, 64.0%) and 78.0% (95% confidence interval: 75.7%, 80.4%), respectively. Comparison of performance showed that the model with imaging findings performed significantly better than did the model with clinical variables alone (P

AB - Purpose: To determine whether magnetic resonance (MR) imaging and MR spectroscopic imaging findings can improve predictions made with the Kattan nomogram for radiation therapy. Materials and Methods: The institutional review board approved this retrospective HIPAA-compliant study. Ninety-nine men who underwent endorectal MR and MR spectroscopy before externalbeam radiation therapy for prostate cancer (January 1998 to June 2007) were included. Linear predictors were calculated with input variables from the study sample and the Kattan original coefficients. The linear predictor is a single weighted value that combines information of all predictor variables in a model, where the weight of each value is its association with the outcome. Two radiologists independently reviewed all MR images to determine extent of disease; a third independent reader resolved discrepancies. Biochemical failure was defined as a serum prostate-specific antigen level of 2 ng/mL (2 μg/L) or more above nadir. Cox proportional hazard models were used to determine the probabilities of treatment failure (biochemical failure) in 5 years. One model included only the Kattan nomogram data; the other also incorporated imaging findings. The discrimination performance of all models was determined with receiver operating characteristics (ROC) curve analyses. These analyses were followed by an assessment of net risk reclassification. Results: The areas under the ROC curve for the Kattan nomogram and the model incorporating MR imaging findings were 61.1% (95% confidence interval: 58.1%, 64.0%) and 78.0% (95% confidence interval: 75.7%, 80.4%), respectively. Comparison of performance showed that the model with imaging findings performed significantly better than did the model with clinical variables alone (P

UR - http://www.scopus.com/inward/record.url?scp=80054791110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054791110&partnerID=8YFLogxK

U2 - 10.1148/radiol.11110457

DO - 10.1148/radiol.11110457

M3 - Article

VL - 261

SP - 477

EP - 486

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 2

ER -